New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 28, 2014
05:30 EDTVRX, AGN, NSRGYValeant to sell filler, toxin assets to Nestle for $1.4B in cash
Valeant Pharmaceuticals (VRX) announced that it has entered into an agreement with Nestle S.A. (NSRGY) to sell all rights to Restylane, Perlane, Emervel, Sculptra, and Dysport owned or held by Valeant for $1.4B in cash. Nestle expects to complete its acquisition of Galderma S.A. in July and would expect to operate the acquired assets through Galderma. The transaction is subject to customary closing conditions, including clearance or early expiration of the waiting period under the Hart-Scott-Rodino Act and is not contingent upon a successful transaction with Allergan (AGN). Valeant believes that this transaction is extremely attractive both to Valeant and Galderma, and dovetails well with the company's announced plans for a transaction with Allergan.
News For VRX;NSRGY;AGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
January 30, 2015
07:29 EDTVRXValeant selected as lead bidder to acquire Dendreon, Provenge for $296M
Subscribe for More Information
05:20 EDTVRXDendreon reaches agreement for Valeant to serve as 'stalking horse bidder'
Subscribe for More Information
January 26, 2015
17:34 EDTAGNActavis registration statement for Allergan acquisition declared effective
Subscribe for More Information
January 22, 2015
05:57 EDTVRXActavis, Valeant raise prospects of more healthcare deals, Financial Times says
Subscribe for More Information
January 21, 2015
12:30 EDTAGN, VRXGlaxoSmithKline 'admired' by Pfizer CEO, FT reports
Subscribe for More Information
07:22 EDTAGNActavis price target raised to $330 from $280 at Deutsche Bank
Subscribe for More Information
January 20, 2015
06:51 EDTNSRGYNestle to invest about $140M in Egypt over next few years, Reuters says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use